Intelligence for decisions, partnerships and market expansion.
Economic reporting from around the world, filtered to the sectors and policy areas our members build in — part of the same intelligence stream behind the Global Economic Outlook and NiDCC's market reports.
life_sciences — September 13, 2026, 2:43 PM · WSJ
Pfizer is taking an unusual approach to recover payment for unwanted Covid-19 vaccines, targeting air-traffic control fees in its dispute with Poland and Romania. The drugmaker is trying to enforce pandemic-era contracts for over 90 million shots that are no longer needed, a move that regulators in the two countries warn could jeopardize air safety.
Explore more
life_sciences — September 13, 2026, 2:36 PM · 24/7 Wall St.
This article compares two medical device dividend giants, Medtronic (MDT) and Abbott Laboratories (ABT), to determine which is the better buy for retirement investors. It analyzes their dividends, underlying businesses, and valuations, concluding that Medtronic offers a higher yield and lower earnings multiple, making it suitable for income investors. Abbott, with its longer dividend streak and diversified business, is presented as a better option for those in accumulation mode with a long investment horizon.
Explore more
life_sciences — September 13, 2026, 1:24 PM · The National Law Review
Faruqi & Faruqi, LLP reminds investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that the lead plaintiff deadline in a securities class action lawsuit is September 14, 2026. The lawsuit alleges that Regeneron made misleading statements regarding its Phase III Fianlimab-Libtayo Study, which subsequently failed to meet its primary endpoint, causing significant stock price drops. Investors who purchased Regeneron securities between August 1, 2025, and May 15, 2026, are encouraged to contact the firm to discuss their legal options.
Explore more
life_sciences — September 13, 2026, 11:07 AM · Speciality Chemicals Magazine
Chemours, DuPont, and Corteva have agreed to a $455 million settlement to resolve litigation concerning per- and polyfluoroalkyl substances (PFAS) and other historical discharges from the Fayetteville Works in North Carolina. This agreement includes $18 million for PFAS contamination unrelated to Fayetteville and addresses lawsuits brought by the State of North Carolina and 11 local entities. Chemours will pay 50% of the settlement, with DuPont and Corteva covering the remaining 50%, reflecting an earlier Memorandum of Understanding between the companies.
Explore more
life_sciences — September 13, 2026, 10:29 AM · Radiology Business
RadNet Inc. has appointed Kees Wesdorp, PhD, a leader from private equity firm Hellman & Friedman, as the new president and CEO of its Digital Health Division. Wesdorp, who previously held business leadership roles at Philips, will join RadNet's executive management team and oversee digital products and services in radiology informatics and AI. He will be based in the Netherlands and his employment term begins October 1st, with a significant compensation package including base salary, bonuses, and stock units.
Explore morelife_sciences — September 13, 2026, 9:08 AM · Yahoo Finance
Novartis has paid Monte Rosa Therapeutics a $50 million milestone payment after dosing the first patient in a Phase 2 trial for MRT-6160, a VAV1-targeted drug for Sjögren's disease. This is part of a larger deal potentially worth up to $2.1 billion. While Monte Rosa is advancing other pipeline candidates and has sufficient cash into 2029, the company faces growing losses and mixed investor sentiment regarding its future trajectory.
Explore more
life_sciences — September 13, 2026, 6:59 AM · Kalkine Media
Pfizer is at a critical juncture where its valuation is heavily influenced by its evolving pipeline, especially in oncology and vaccines, alongside ongoing portfolio reshaping. The core question is whether the market's current valuation of Pfizer fully accounts for the future success of these new therapies and how effectively the company can replace maturing products. Competition in the pharmaceutical industry and the need for continuous innovation further complicate this valuation debate.
Explore more
life_sciences — September 13, 2026, 4:45 AM · Simply Wall Street
Amgen's stock is under scrutiny following new Phase 3 IMDELLTRA data showing improved overall and progression-free survival in lung cancer, but also after recent share price volatility. While one valuation model suggests a slight overvaluation at $359.98, another Discounted Cash Flow model indicates significant undervaluation at $669.81. The article highlights key risks to the bullish "Amgen 2027 Bull Case," particularly concerning manufacturing capacity for obesity drugs and regulatory uncertainties.
Explore more
life_sciences — September 13, 2026, 12:38 AM · ACCESS Newswire
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo study, which was unlikely to achieve statistical significance. Investors who suffered losses are encouraged to join the lawsuit by September 14, 2026, to potentially be appointed as lead plaintiff.
Explore more
life_sciences — September 12, 2026, 10:08 PM · Investing.com
Metagenomi Therapeutics director Laurence Reid recently purchased 20,000 shares of company stock for a total of $23,401, with prices ranging from $1.17 to $1.18 per share. This transaction occurred as the stock trades near its 52-week low. The company recently reported a larger-than-expected net loss in Q2 2026, leading Wells Fargo to lower its price target, while Chardan initiated coverage with a buy rating based on the potential of its lead asset, MGX-001.
Explore more